BioSpace News Archive

Freeline Therapeutics Holdings plc announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares.

AnaptysBio, Inc. announced a portfolio update including initiating development of its wholly owned best-in-class immune cell modulating antibodies in autoimmune and inflammatory diseases with large and significantly underserved patient populations.

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of prurigo nodularis, announced business updates.

Rani Therapeutics Holdings, Inc. announced that it completed a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration with respect to RT-102, the RaniPill™ GO containing a proprietary formulation of human parathyroid hormone analog for the potential treatment of osteoporosis, and provided a corporate update.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced the appointment of Rita Jain, M.D., to the Company’s Board of Directors.

Adagene Inc. announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference.

Sensus Healthcare, Inc. reports preliminary 2022 fourth quarter and full year revenues.

Terns Pharmaceuticals, Inc. announced that management will provide an update on its pipeline and strategic priorities for 2023 during the Company’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023 at 9:00am PT.